Design and development of novel therapeutics for coronary heart disease treatment based on cholesteryl ester transfer protein inhibition - in silico approach

被引:4
作者
Kostic, Tomislav [1 ]
Ilic, Marina Deljanin [2 ]
Perisic, Zoran [1 ]
Milic, Dragan [3 ]
Dordevic, Miodrag [4 ]
Golubovic, Mladjan [5 ]
Koracevic, Goran [1 ]
Martinovic, Sonja Salinger [1 ]
Zdravkovic, Snezana Ciric [1 ]
Zivic, Sasa [3 ]
Lazarevic, Milan [3 ]
Stanojevic, Dragana [1 ]
Dakic, Sonja [1 ]
Lilic, Jelena [5 ]
Veselinovic, Aleksandar [6 ]
机构
[1] Clin Ctr Nis, Clin Cardiovasc Dis, Nish, Serbia
[2] Inst Cardiovasc Prevent & Rehabil Niska Banja, Nish, Serbia
[3] Clin Ctr Nis, Clin Cardiovasc Surg, Nish, Serbia
[4] Clin Ctr Nis, Clin Endocrine Surg & Breast Surg, Nish, Serbia
[5] Clin Ctr Nis, Clin Anesthesiol & Intens Care, Nish, Serbia
[6] Univ Nis, Fac Med, Dept Chem, Bulevar Dr Zorana Dindica 81, Nish 18000, Serbia
关键词
Cholesteryl ester transfer protein inhibitors; coronary heart disease therapy; QSAR; molecular modeling; drug design; MONTE-CARLO METHOD; DRUG DISCOVERY; VARIABLE SELECTION; QSAR; HDL; VALIDATION; PRINCIPLES; DOCKING; 3D-QSAR; TARGET;
D O I
10.1080/07391102.2019.1630319
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cholesteryl ester transfer protein (CETP) belongs to the group of enzymes which inhibition have the application in the treatment of cardiovascular diseases. This study presents QSAR modeling for a set of compounds acting as CETP inhibitors based on the Monte Carlo optimization with SMILES notation and molecular graph-based descriptors, and field-based 3D modeling. A 3D QSAR model was developed for one random split into the training and test sets, whereas conformation independent QSAR models were developed for three random splits, with the results suggesting there is an excellent correlation between them. Various statistical approaches were used to assess the statistical quality of the developed models, including robustness and predictability, and the obtained results were very good. This study used a novel statistical metric known as the index of ideality of correlation for the final assessment of the model, and the results that were obtained suggested that the model was good. Also, molecular fragments which account for the increases and/or decreases of a studied activity were defined and then used for the computer-aided design of new compounds as potential CETP inhibitors. The final assessment of the developed QSAR model and designed inhibitors was done using molecular docking, which revealed an excellent correlation with the results from QSAR modeling. Communicated by Ramaswamy H. Sarma
引用
收藏
页码:2304 / 2313
页数:10
相关论文
共 60 条
  • [1] Designing potential HDAC3 inhibitors to improve memory and learning
    Amin, Sk. Abdul
    Adhikari, Nilanjan
    Jha, Tarun
    Ghosh, Balaram
    [J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2019, 37 (08) : 2133 - 2142
  • [2] Pharmacoinformatics study of Piperolactam A from Piper betle root as new lead for non steroidal anti fertility drug development
    Amin, Sk. Abdul
    Bhattacharya, Plaban
    Basak, Souvik
    Gayen, Shovanlal
    Nandy, Ashis
    Saha, Achintya
    [J]. COMPUTATIONAL BIOLOGY AND CHEMISTRY, 2017, 67 : 213 - 224
  • [3] Exploring pyrazolo[3,4-d]pyrimidine phosphodiesterase 1 (PDE1) inhibitors: a predictive approach combining comparative validated multiple molecular modelling techniques
    Amin, Sk. Abdul
    Bhargava, Sonam
    Adhikari, Nilanjan
    Gayen, Shovanlal
    Jha, Tarun
    [J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2018, 36 (03) : 590 - 608
  • [4] The recent trend in QSAR modeling - Variable selection and 3D-QSAR methods
    Arakawa, Masamoto
    Hasegawa, Kiyoshi
    Funatsu, Kimito
    [J]. CURRENT COMPUTER-AIDED DRUG DESIGN, 2007, 3 (04) : 254 - 262
  • [5] Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now?
    Barter, Philip
    Rye, Kerry-Anne
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2011, 32 (12) : 694 - 699
  • [6] New Era of Lipid-Lowering Drugs
    Barter, Philip J.
    Rye, Kerry-Anne
    [J]. PHARMACOLOGICAL REVIEWS, 2016, 68 (02) : 458 - 475
  • [7] Cholesteryl ester transfer protein - A novel target for raising HDL and inhibiting atherosclerosis
    Barter, PJ
    Brewer, HB
    Chapman, MJ
    Hennekens, CH
    Rader, DJ
    Tall, AR
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (02) : 160 - 167
  • [8] QSAR Modeling: Where Have You Been? Where Are You Going To?
    Cherkasov, Artem
    Muratov, Eugene N.
    Fourches, Denis
    Varnek, Alexandre
    Baskin, Igor I.
    Cronin, Mark
    Dearden, John
    Gramatica, Paola
    Martin, Yvonne C.
    Todeschini, Roberto
    Consonni, Viviana
    Kuz'min, Victor E.
    Cramer, Richard
    Benigni, Romualdo
    Yang, Chihae
    Rathman, James
    Terfloth, Lothar
    Gasteiger, Johann
    Richard, Ann
    Tropsha, Alexander
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (12) : 4977 - 5010
  • [9] High-Density Lipoproteins: Biology, Epidemiology, and Clinical Management
    Choi, Hong Y.
    Hafiane, Anouar
    Schwertani, Adel
    Genest, Jacques
    [J]. CANADIAN JOURNAL OF CARDIOLOGY, 2017, 33 (03) : 325 - 333
  • [10] The inevitable QSAR renaissance
    Cramer, Richard D.
    [J]. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2012, 26 (01) : 35 - 38